A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Trial details
- Registry ID
- NCT05178862
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Ibrexafungerp
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleNCT05178862 | SCYX | Phase 3 | Terminated | 2025-11-07Actual |
| Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary AspergillosisNCT03672292 | SCYX | Phase 2 | Terminated | 2023-03-27Actual |
| Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)NCT03363841 | SCYX | Phase 3 | Completed | 2023-04-14Actual |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisNCT02244606 | SCYX | Phase 2 | Completed | 2016-06Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |